Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Checkpoint Therapeutics, Inc. (CKPT)
|
Add to portfolio |
|
|
|
| Price: |
$3.11
| | Metrics |
| OS: |
21.6
|
M
| |
|
|
| Market cap: |
$67.2
|
M
| |
|
|
|
Net cash:
|
$7.42
|
M
| |
$0.34
|
per share
|
|
EV:
|
$59.7
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($61.6)
|
M
| |
|
|
|
EBIT
|
($61.6)
|
M
| |
|
|
| EPS |
($4.44)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.2 | 0.3 | 1.1 | 1.7 | 3.5 | 1.7 | 2.6 | 0.6 |
| Revenue growth | -28.4% | -74.9% | -37.4% | -51.3% | 103.2% | -32.9% | 335.6% | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.2 | 0.3 | 1.1 | 1.7 | 3.5 | 1.7 | 2.6 | 0.6 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | 49.8 | 48.5 | 16.4 | 19.3 | 33.7 | 19.1 | 20.3 | 11.3 |
| General and administrative | 8.7 | 8.5 | 7.9 | 7.2 | 6.6 | 5.4 | 4.5 | 2.5 |
| EBIT | -58.3 | -56.7 | -23.2 | -24.9 | -36.7 | -22.8 | -22.2 | -13.2 |
| EBIT margin | -30381.8% | -21165.3% | -2170.3% | -1454.9% | -1047.9% | -1320.3% | -862.4% | -2240.8% |
| Pre-tax income | -62.6 | -56.7 | -23.1 | -24.7 | -36.4 | -22.7 | -22.5 | -13.9 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -62.6 | -56.7 | -23.1 | -24.7 | -36.4 | -22.7 | -22.5 | -13.9 |
| Net margin | -32616.7% | -21145.5% | -2159.1% | -1447.0% | -1037.3% | -1314.6% | -874.0% | -2354.6% |
| |
| Diluted EPS | ($7.09) | ($7.45) | ($0.41) | ($0.70) | ($1.27) | ($1.00) | ($1.04) | ($1.41) |
| Shares outstanding (diluted) | 8.8 | 7.6 | 55.8 | 35.3 | 28.6 | 22.6 | 21.5 | 9.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|